Hungarian pharmaceutical company Chinoin, which is part of the Frenchgroup Sanofi, achieved record international sales of 5.9 billion forint ($321.3 million) in the first four months of the current year. Domestic sales were 4.7 billion forint, reports MTI Econews.
Last year, the firm recorded revenues of 23.8 billion forint. Chinoin has an 8.2% stake in the Hungarian drugs market. Over-the-counter medicines account for 35% of the firm's domestic sales, with half of its exports going to eastern Europe, particularly the CIS.
Operating profit increased 1.2 billion forint last year to 6.5 billion forint, it was noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze